Vector Prime/Protein Boost Vaccine That Overcomes Defects Acquired during Aging and Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Vector Prime/Protein Boost Vaccine That Overcomes Defects Acquired during Aging and Cancer

Published:2006-10-02 Issue:8 Volume:177 Page:5697-5707
ISSN:0022-1767
Container-title:The Journal of Immunology
language:en
Short-container-title:J Immunol

Author:

Tang Yucheng,Akbulut Hakan,Maynard Jonathan,Petersen Line,Fang Xiangming,Zhang Wei-Wei,Xia Xiaoqin,Koziol James,Linton Phyllis-Jean,Deisseroth Albert

Publisher

The American Association of Immunologists

Subject

Immunology,Immunology and Allergy

Reference25 articles.

1. An immunostimulatory oligodeoxynucleotide containing a cytidine-guanosine motif protects senescence-accelerated mice from lethal influenza virus by augmenting the T helper type 1 response

2. Multistep process through which adenoviral vector vaccine overcomes anergy to tumor-associated antigens

3. Maturation of Dendritic Cells by Recombinant Human CD40L-Trimer Leads to a Homogeneous Cell Population with Enhanced Surface Marker Expression and Increased Cytokine Production

4. Structural characteristics of CD40 ligand that determine biological function

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preclinical Toxicology of Vaccines;A Comprehensive Guide to Toxicology in Nonclinical Drug Development;2024

2. A phase I study of an adenoviral vector delivering a MUC1/CD40-ligand fusion protein in patients with advanced adenocarcinoma;Nature Communications;2022-10-28

3. Immune gene therapy of cancer;TURKISH JOURNAL OF MEDICAL SCIENCES;2020-11-03

4. Cancer Immunotherapy – The Target is Precisely on The Cancer and Also Not;Annals of the Academy of Medicine, Singapore;2018-09-15

5. Preclinical Toxicology of Vaccines 1 1Disclaimer: The findings and conclusions in this chapter have not been formally disseminated by the Food and Drug Administration and should not be construed to represent any Agency determination or policy.;A Comprehensive Guide to Toxicology in Nonclinical Drug Development;2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3